Pacific Biosciences faces a critical financial crossroads, with its balance sheet deteriorating into negative equity of -$33.2M and a cash position of only $61.0M against $706.1M in total debt as of 2026Q2. While gross margins have recovered from a trough to 3...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | -$0.14-9.4% vs -$0.13 | $39M-9.1% vs $43M |
Q2 2026 May 7, 2026 | -$0.03+82.4% vs -$0.17 | $37M-6.9% vs $40M |
Q1 2026 Feb 12, 2026 | -$0.12+36.8% vs -$0.19 | $45M+3.7% vs $43M |
Q4 2025 Nov 5, 2025 | -$0.12+25.0% vs -$0.16 | $38M-13.8% vs $45M |
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York.
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
Benchmark PACB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pacific Biosciences of California, Inc. (PACB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.47 | $456.58M | -0.81 | 3.89% | -341.47% | -213.45% | — | |
| $247.46 | $37.44B | 45.41 | -0.78% | 18.36% | 31.08% | — | |
| $9.93 | $2.64B | -32.03 | 18.96% | -66.74% | -38.36% | — | |
| $56.49 | $2.92B | -141.23 | 13.79% | 24.23% | 32.81% | — | |
| $658.52 | $244.72B | 37.12 | 3.91% | 15.06% | 13.33% | — | |
| $221.12 | $155.44B | 43.87 | 2.9% | 15.95% | 7.66% | — |
Pacific Biosciences of California, Inc. (PACB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Pacific Biosciences of California, Inc. (PACB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 9, 2026·SEC
Jun 4, 2026·SEC
Get notified when PACB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pacific Biosciences of California, Inc. (PACB) stock FAQ — growth, dividends, profitability & financials explained
Pacific Biosciences of California, Inc. (PACB) reported $159.3M in revenue for fiscal year 2025. This represents a 17577% increase from $0.9M in 2008.
Pacific Biosciences of California, Inc. (PACB) grew revenue by 3.9% over the past year. Growth has been modest.
Pacific Biosciences of California, Inc. (PACB) reported a net loss of $131.4M for fiscal year 2025.
Pacific Biosciences of California, Inc. (PACB) has a return on equity (ROE) of -213.5%. Negative ROE indicates the company is unprofitable.
Pacific Biosciences of California, Inc. (PACB) had negative free cash flow of $171.2M in fiscal year 2025, likely due to heavy capital investments.
